[8-K] Immucell Corp Reports Material Event

Rhea-AI Filing Summary

ImmuCell Corporation (NASDAQ:ICCC) filed an 8-K announcing the initiation of a CEO succession planning process. The filing discloses that current President and CEO Michael F. Brigham will be part of this transition. The company has begun searching for new leadership, though no specific timeline was provided. This represents a significant corporate governance development for ImmuCell, as leadership transitions can materially impact company strategy and operations.

Insights

Corporate Governance Expert

CEO succession announcement signals proactive leadership planning but creates temporary uncertainty around future direction.

The initiation of a formal CEO succession process represents a critical inflection point for ImmuCell. While succession planning is a standard corporate governance practice, the timing and public announcement suggest this is an active rather than theoretical exercise. The involvement of the current CEO in the announcement indicates this may be a planned transition rather than an unexpected departure, which typically allows for more orderly leadership changes. Investors should monitor subsequent announcements for details about the search timeline, candidate criteria, and transition plan to assess potential impacts on company strategy and operations.

false 0000811641 0000811641 2025-06-25 2025-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 25, 2025

ImmuCell Corporation

(Exact name of registrant as specified in its charter)

DE		001-12934		01-0382980
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

56 Evergreen Drive Portland, Maine		04103
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code 207-878-2770

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, $0.10 par value per share		ICCC		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01.  Other Events

On June 25, 2025 ImmuCell Corporation (the “Company”) issued a press release announcing its CEO Succession Planning Process.

The information in Item 8.01 and Exhibit 99.1 to this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01.  Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit relating to Item 8.01 shall be deemed to be furnished, and not filed:

99.1 Press Release of ImmuCell Corporation dated June 25, 2025.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 25, 2025	IMMUCELL CORPORATION
	By:	/s/ Michael F. Brigham
		President and Chief Executive Officer
	By:	/s/ Timothy C. Fiori
		Chief Financial Officer

2

Exhibit Index

Exhibit No.		Description
99.1		Press Release of ImmuCell Corporation dated June 25, 2025

3

FAQ

Why is ImmuCell (ICCC) announcing CEO succession planning?

ImmuCell has initiated a CEO succession planning process, though specific reasons for the timing were not disclosed in the filing. This appears to be a proactive governance measure with current CEO Michael F. Brigham's involvement.

Who is the current CEO of ImmuCell (ICCC)?

Michael F. Brigham is the current President and Chief Executive Officer of ImmuCell Corporation, as confirmed by his signature on the 8-K filing.

Has ImmuCell (ICCC) announced a timeline for the CEO transition?

No specific timeline for the CEO transition has been disclosed in the 8-K filing.

Will ImmuCell's (ICCC) current CEO remain during the transition?

Based on the filing, current CEO Michael F. Brigham remains in his position as President and Chief Executive Officer during the succession planning process.